Q1 Earnings Estimate for Zymeworks Issued By Lifesci Capital

Zymeworks Inc. (NYSE:ZYME) – Investment analysts at Lifesci Capital issued their Q1 2025 earnings estimates for shares of Zymeworks in a research note issued to investors on Tuesday, March 11th. Lifesci Capital analyst C. Zhu anticipates that the company will post earnings per share of ($0.50) for the quarter. Lifesci Capital currently has a “Outperform” rating and a $30.00 price target on the stock. The consensus estimate for Zymeworks’ current full-year earnings is ($1.39) per share. Lifesci Capital also issued estimates for Zymeworks’ Q2 2025 earnings at ($0.58) EPS, Q3 2025 earnings at ($0.62) EPS, Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.36) EPS, Q1 2026 earnings at $0.50 EPS, Q2 2026 earnings at ($0.83) EPS, Q3 2026 earnings at ($0.85) EPS, Q4 2026 earnings at ($0.81) EPS and FY2026 earnings at ($1.77) EPS.

A number of other brokerages have also recently commented on ZYME. Citigroup lifted their price target on Zymeworks from $18.00 to $19.00 and gave the stock a “buy” rating in a research report on Friday, March 7th. JPMorgan Chase & Co. raised Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 target price for the company in a report on Monday, December 16th. Wells Fargo & Company increased their price target on shares of Zymeworks from $12.00 to $14.00 and gave the stock an “equal weight” rating in a report on Thursday, December 19th. Finally, HC Wainwright raised their price target on shares of Zymeworks from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Monday. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Zymeworks currently has an average rating of “Moderate Buy” and a consensus price target of $21.00.

Zymeworks Trading Up 2.2 %

NYSE ZYME opened at $12.55 on Thursday. The stock has a market cap of $873.19 million, a P/E ratio of -8.37 and a beta of 1.13. Zymeworks has a 12-month low of $7.97 and a 12-month high of $17.70. The company has a fifty day simple moving average of $13.96 and a two-hundred day simple moving average of $13.65.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Polar Asset Management Partners Inc. purchased a new stake in Zymeworks in the 4th quarter worth $527,000. Voloridge Investment Management LLC acquired a new stake in shares of Zymeworks in the fourth quarter valued at about $640,000. Point72 Asset Management L.P. increased its stake in shares of Zymeworks by 565.8% during the fourth quarter. Point72 Asset Management L.P. now owns 330,127 shares of the company’s stock worth $4,833,000 after purchasing an additional 280,544 shares in the last quarter. Nuveen Asset Management LLC raised its position in shares of Zymeworks by 0.4% during the 4th quarter. Nuveen Asset Management LLC now owns 207,023 shares of the company’s stock worth $3,031,000 after purchasing an additional 886 shares during the last quarter. Finally, Deutsche Bank AG lifted its stake in Zymeworks by 1.2% in the 4th quarter. Deutsche Bank AG now owns 1,546,772 shares of the company’s stock valued at $22,645,000 after buying an additional 17,849 shares in the last quarter. 92.89% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Zymeworks

In related news, CEO Kenneth Galbraith sold 57,291 shares of Zymeworks stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $14.92, for a total value of $854,781.72. Following the completion of the transaction, the chief executive officer now owns 47,543 shares in the company, valued at $709,341.56. The trade was a 54.65 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ecor1 Capital, Llc purchased 11,958 shares of Zymeworks stock in a transaction that occurred on Tuesday, December 24th. The stock was acquired at an average cost of $14.12 per share, with a total value of $168,846.96. Following the acquisition, the director now directly owns 14,704,239 shares in the company, valued at $207,623,854.68. This trade represents a 0.08 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 1,392,585 shares of company stock worth $17,914,519 and sold 89,601 shares worth $1,336,847. 1.92% of the stock is owned by company insiders.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.